John Walter Hanna Jr., serving as both President and Chief Executive Officer of CareDx, Inc. (NASDAQ: CDNA), completed a sale of company equity on June 11, 2026. The transaction resulted in the disposal of 21,998 shares of common stock, generating total proceeds of $528,442. The shares were liquidated through multiple executions at prices ranging between $24.00 and $24.11 per share, establishing a weighted average sale price of $24.0223. This disposition was carried out under the terms of a Rule 10b5-1 trading plan that Mr. Hanna originally adopted on December 13, 2024.
Post-transaction, Mr. Hanna retains direct ownership of 649,642 shares of CareDx common stock. The sale activity takes place while CareDx shares are trading at $24.08, a level close to the stock's 52-week high of $24.13. Shares have climbed nearly 22% year-to-date. Market analysis from InvestingPro suggests the stock is currently trading above its calculated Fair Value, positioning it within lists of overvalued equities. Detailed valuation metrics and additional ProTips are available through the comprehensive Pro Research Report.
Financial performance for the first quarter of 2026 demonstrated significant strength, with CareDx reporting results that materially exceeded analyst forecasts. The company posted an earnings per share (EPS) of $0.34, a substantial deviation from the consensus estimate of -$0.06, resulting in a 666.67% surprise. Total revenue for the quarter reached $117.7 million, surpassing the anticipated $104.12 million by a 13.04% margin. Testing revenue experienced a 48% year-over-year increase to $91.4 million, while patient and digital solutions revenue grew by 33% to $16.0 million. Conversely, product revenue declined by 4% to $10.3 million.
Corporate developments include the announcement of an acquisition deal with Naveris, valued at up to $260 million. The transaction structure comprises $160 million in cash and $100 million in milestones. This strategic move prompted BTIG to increase its price target for CareDx to $28.00, while maintaining a Buy rating. In contrast, H.C. Wainwright reiterated a Neutral rating on the stock following the financial results release. Additionally, shareholders approved an amendment to the 2024 Equity Incentive Plan, increasing the reserved share count by 1,600,000.